161 related articles for article (PubMed ID: 9618530)
1. Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: an MRI study.
Ross BD; Zhao YJ; Neal ER; Stegman LD; Ercolani M; Ben-Yoseph O; Chenevert TL
Proc Natl Acad Sci U S A; 1998 Jun; 95(12):7012-7. PubMed ID: 9618530
[TBL] [Abstract][Full Text] [Related]
2. Growth kinetics and treatment response of the intracerebral rat 9L brain tumor model: a quantitative in vivo study using magnetic resonance imaging.
Kim B; Chenevert TL; Ross BD
Clin Cancer Res; 1995 Jun; 1(6):643-50. PubMed ID: 9816027
[TBL] [Abstract][Full Text] [Related]
3. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging.
Chenevert TL; McKeever PE; Ross BD
Clin Cancer Res; 1997 Sep; 3(9):1457-66. PubMed ID: 9815831
[TBL] [Abstract][Full Text] [Related]
4. In vivo clonogenic tumor cell kinetics following 1,3-bis(2-chloroethyl)-1-nitrosourea brain tumor therapy.
Rosenblum ML; Knebel KD; Vasquez DA; Wilson CB
Cancer Res; 1976 Oct; 36(10):3718-25. PubMed ID: 953998
[TBL] [Abstract][Full Text] [Related]
5. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging.
Rehemtulla A; Stegman LD; Cardozo SJ; Gupta S; Hall DE; Contag CH; Ross BD
Neoplasia; 2000; 2(6):491-5. PubMed ID: 11228541
[TBL] [Abstract][Full Text] [Related]
6. Measurement of sister chromatid exchange induction in intracerebral brain tumors as a method for evaluation of therapeutic drug combinations.
Bodell WJ
Anticancer Res; 2000; 20(5A):3099-103. PubMed ID: 11062728
[TBL] [Abstract][Full Text] [Related]
7. Laboratory studies of berberine used alone and in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea to treat malignant brain tumors.
Zhang RX; Dougherty DV; Rosenblum ML
Chin Med J (Engl); 1990 Aug; 103(8):658-65. PubMed ID: 2122945
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker.
Hall DE; Moffat BA; Stojanovska J; Johnson TD; Li Z; Hamstra DA; Rehemtulla A; Chenevert TL; Carter J; Pietronigro D; Ross BD
Clin Cancer Res; 2004 Dec; 10(23):7852-9. PubMed ID: 15585617
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of the antitumor therapeutic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea by alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor.
Marton LJ; Levin VA; Hervatin SJ; Koch-Weser J; McCann PP; Sjoerdsma A
Cancer Res; 1981 Nov; 41(11 Pt 1):4426-31. PubMed ID: 6796258
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of in vivo brain tumor chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Rosenblum ML; Wheeler KT; Wilson CB; Barker M; Knebel KD
Cancer Res; 1975 Jun; 35(6):1387-91. PubMed ID: 1131813
[TBL] [Abstract][Full Text] [Related]
11. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Chenevert TL; Stegman LD; Taylor JM; Robertson PL; Greenberg HS; Rehemtulla A; Ross BD
J Natl Cancer Inst; 2000 Dec; 92(24):2029-36. PubMed ID: 11121466
[TBL] [Abstract][Full Text] [Related]
12. Invasive phenotype observed in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant sublines of 9L rat glioma cells: a tumor model mimicking a recurrent malignant glioma.
Saito R; Bringas J; Mirek H; Berger MS; Bankiewicz KS
J Neurosurg; 2004 Nov; 101(5):826-31. PubMed ID: 15540922
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on the 9L rat brain tumor model using MRI.
Ross BD; Chenevert TL; Garwood M; Kim B; Stegman LD; Ben-Yoseph O; Zwolshen J; Rehemtulla A; Sunkara PS
NMR Biomed; 2003 Apr; 16(2):67-76. PubMed ID: 12730947
[TBL] [Abstract][Full Text] [Related]
14. Response of 9L rat brain tumor multicellular spheroids to single and fractionated doses of 1,3-bis(2-chloroethyl)-1-nitrosourea.
Sano Y; Hoshino T; Barker M; Deen DF
Cancer Res; 1984 Feb; 44(2):571-6. PubMed ID: 6692362
[TBL] [Abstract][Full Text] [Related]
15. Sodium magnetic resonance imaging of chemotherapeutic response in a rat glioma.
Schepkin VD; Ross BD; Chenevert TL; Rehemtulla A; Sharma S; Kumar M; Stojanovska J
Magn Reson Med; 2005 Jan; 53(1):85-92. PubMed ID: 15690506
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea and low dose rate radiation in the 9L rat brain tumor and spheroid models: implications for brain tumor brachytherapy.
Gutin PH; Bernstein M; Sano Y; Deen DF
Neurosurgery; 1984 Dec; 15(6):781-6. PubMed ID: 6514150
[TBL] [Abstract][Full Text] [Related]
17. Improved treatment of a brain-tumor model. Part 1: Advantages of single- over multiple-dose BCNU schedules.
Rosenblum ML; Gerosa MA; Dougherty DV; Wilson CB
J Neurosurg; 1983 Feb; 58(2):177-82. PubMed ID: 6848673
[TBL] [Abstract][Full Text] [Related]
18. The 9L rat brain tumor: description and application of an animal model.
Weizsaecker M; Deen DF; Rosenblum ML; Hoshino T; Gutin PH; Barker M
J Neurol; 1981; 224(3):183-92. PubMed ID: 6162014
[TBL] [Abstract][Full Text] [Related]
19. BCNU and X-ray therapy of intracerebral 9L rat tumors.
Barker M; Deen DF; Baker DG
Int J Radiat Oncol Biol Phys; 1979 Sep; 5(9):1581-3. PubMed ID: 536266
[No Abstract] [Full Text] [Related]
20. Earlier detection of tumor treatment response using magnetic resonance diffusion imaging with oscillating gradients.
Colvin DC; Loveless ME; Does MD; Yue Z; Yankeelov TE; Gore JC
Magn Reson Imaging; 2011 Apr; 29(3):315-23. PubMed ID: 21190804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
